Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

PD-1 inhibitor is safe, shrank tumors or stabilized disease in most patients The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shran...

April 22, 2015 by moderator with 0 comments

Investigational personalized cellular therapy tolerated well by patients

Promising results of Phase I trial show successful migration of immune cells to tumor sites Genetically modified versions of patients’ own ...

April 22, 2015 by moderator with 0 comments

Asbestos use in Asia poses serious health dangers

The use of asbestos continues to increase in Asia despite clear health hazards. A recent Respirology review notes that with approximately 4.3 bil...

April 10, 2015 by moderator with 0 comments